USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include c...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; pol |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE CASTELLANOS SERRA, LILA ROSA PEREA RODRÍGUEZ, SILVIO ERNESTO GONZÁLEZ LÓPEZ, LUIS JAVIER RAMOS GÓMEZ, YASSEL BETANCOURT NÚÑEZ, LÁZARO HIRAM PERERA NEGRÍN, YASSER GOMEZ, DANIEL EDUARDO SÁNCHEZ PUENTE, ANIEL GIL VALDÉS, JEOVANIS RODRÍGUEZ ULLOA, ARIELIS ALONSO, DANIEL FERNANDO BESADA PÉREZ, VLADIMIR ACEVEDO CASTRO, BORIS ERNESTO |
| description | This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PL1997506TT3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PL1997506TT3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PL1997506TT33</originalsourceid><addsrcrecordid>eNqNy0EKwjAQheFsXIh6h_EAglpUuozpxATbRCaThW5KkYgL0UK9P0bwAC4eb_N_Y3GPAcFrUMc1WGfs3rIn0HlsEJhQcoOOQboKlMHGB3QhV7W9SLbefS2hJqmyOwPHxlMA9hmwVdIpJKgoHsJUjG7dY0iz30_EXCMrs0j9q01D313TM73bU70qy91muWUuin-aDyJaNj8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS</title><source>esp@cenet</source><creator>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE ; CASTELLANOS SERRA, LILA ROSA ; PEREA RODRÍGUEZ, SILVIO ERNESTO ; GONZÁLEZ LÓPEZ, LUIS JAVIER ; RAMOS GÓMEZ, YASSEL ; BETANCOURT NÚÑEZ, LÁZARO HIRAM ; PERERA NEGRÍN, YASSER ; GOMEZ, DANIEL EDUARDO ; SÁNCHEZ PUENTE, ANIEL ; GIL VALDÉS, JEOVANIS ; RODRÍGUEZ ULLOA, ARIELIS ; ALONSO, DANIEL FERNANDO ; BESADA PÉREZ, VLADIMIR ; ACEVEDO CASTRO, BORIS ERNESTO</creator><creatorcontrib>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE ; CASTELLANOS SERRA, LILA ROSA ; PEREA RODRÍGUEZ, SILVIO ERNESTO ; GONZÁLEZ LÓPEZ, LUIS JAVIER ; RAMOS GÓMEZ, YASSEL ; BETANCOURT NÚÑEZ, LÁZARO HIRAM ; PERERA NEGRÍN, YASSER ; GOMEZ, DANIEL EDUARDO ; SÁNCHEZ PUENTE, ANIEL ; GIL VALDÉS, JEOVANIS ; RODRÍGUEZ ULLOA, ARIELIS ; ALONSO, DANIEL FERNANDO ; BESADA PÉREZ, VLADIMIR ; ACEVEDO CASTRO, BORIS ERNESTO</creatorcontrib><description>This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.</description><language>eng ; pol</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2013</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130430&DB=EPODOC&CC=PL&NR=1997506T3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130430&DB=EPODOC&CC=PL&NR=1997506T3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE</creatorcontrib><creatorcontrib>CASTELLANOS SERRA, LILA ROSA</creatorcontrib><creatorcontrib>PEREA RODRÍGUEZ, SILVIO ERNESTO</creatorcontrib><creatorcontrib>GONZÁLEZ LÓPEZ, LUIS JAVIER</creatorcontrib><creatorcontrib>RAMOS GÓMEZ, YASSEL</creatorcontrib><creatorcontrib>BETANCOURT NÚÑEZ, LÁZARO HIRAM</creatorcontrib><creatorcontrib>PERERA NEGRÍN, YASSER</creatorcontrib><creatorcontrib>GOMEZ, DANIEL EDUARDO</creatorcontrib><creatorcontrib>SÁNCHEZ PUENTE, ANIEL</creatorcontrib><creatorcontrib>GIL VALDÉS, JEOVANIS</creatorcontrib><creatorcontrib>RODRÍGUEZ ULLOA, ARIELIS</creatorcontrib><creatorcontrib>ALONSO, DANIEL FERNANDO</creatorcontrib><creatorcontrib>BESADA PÉREZ, VLADIMIR</creatorcontrib><creatorcontrib>ACEVEDO CASTRO, BORIS ERNESTO</creatorcontrib><title>USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS</title><description>This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2013</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNy0EKwjAQheFsXIh6h_EAglpUuozpxATbRCaThW5KkYgL0UK9P0bwAC4eb_N_Y3GPAcFrUMc1WGfs3rIn0HlsEJhQcoOOQboKlMHGB3QhV7W9SLbefS2hJqmyOwPHxlMA9hmwVdIpJKgoHsJUjG7dY0iz30_EXCMrs0j9q01D313TM73bU70qy91muWUuin-aDyJaNj8</recordid><startdate>20130430</startdate><enddate>20130430</enddate><creator>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE</creator><creator>CASTELLANOS SERRA, LILA ROSA</creator><creator>PEREA RODRÍGUEZ, SILVIO ERNESTO</creator><creator>GONZÁLEZ LÓPEZ, LUIS JAVIER</creator><creator>RAMOS GÓMEZ, YASSEL</creator><creator>BETANCOURT NÚÑEZ, LÁZARO HIRAM</creator><creator>PERERA NEGRÍN, YASSER</creator><creator>GOMEZ, DANIEL EDUARDO</creator><creator>SÁNCHEZ PUENTE, ANIEL</creator><creator>GIL VALDÉS, JEOVANIS</creator><creator>RODRÍGUEZ ULLOA, ARIELIS</creator><creator>ALONSO, DANIEL FERNANDO</creator><creator>BESADA PÉREZ, VLADIMIR</creator><creator>ACEVEDO CASTRO, BORIS ERNESTO</creator><scope>EVB</scope></search><sort><creationdate>20130430</creationdate><title>USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS</title><author>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE ; CASTELLANOS SERRA, LILA ROSA ; PEREA RODRÍGUEZ, SILVIO ERNESTO ; GONZÁLEZ LÓPEZ, LUIS JAVIER ; RAMOS GÓMEZ, YASSEL ; BETANCOURT NÚÑEZ, LÁZARO HIRAM ; PERERA NEGRÍN, YASSER ; GOMEZ, DANIEL EDUARDO ; SÁNCHEZ PUENTE, ANIEL ; GIL VALDÉS, JEOVANIS ; RODRÍGUEZ ULLOA, ARIELIS ; ALONSO, DANIEL FERNANDO ; BESADA PÉREZ, VLADIMIR ; ACEVEDO CASTRO, BORIS ERNESTO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PL1997506TT33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; pol</language><creationdate>2013</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE</creatorcontrib><creatorcontrib>CASTELLANOS SERRA, LILA ROSA</creatorcontrib><creatorcontrib>PEREA RODRÍGUEZ, SILVIO ERNESTO</creatorcontrib><creatorcontrib>GONZÁLEZ LÓPEZ, LUIS JAVIER</creatorcontrib><creatorcontrib>RAMOS GÓMEZ, YASSEL</creatorcontrib><creatorcontrib>BETANCOURT NÚÑEZ, LÁZARO HIRAM</creatorcontrib><creatorcontrib>PERERA NEGRÍN, YASSER</creatorcontrib><creatorcontrib>GOMEZ, DANIEL EDUARDO</creatorcontrib><creatorcontrib>SÁNCHEZ PUENTE, ANIEL</creatorcontrib><creatorcontrib>GIL VALDÉS, JEOVANIS</creatorcontrib><creatorcontrib>RODRÍGUEZ ULLOA, ARIELIS</creatorcontrib><creatorcontrib>ALONSO, DANIEL FERNANDO</creatorcontrib><creatorcontrib>BESADA PÉREZ, VLADIMIR</creatorcontrib><creatorcontrib>ACEVEDO CASTRO, BORIS ERNESTO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FERNÁNDEZ DE COSSIO DORTA DUQUE, JORGE</au><au>CASTELLANOS SERRA, LILA ROSA</au><au>PEREA RODRÍGUEZ, SILVIO ERNESTO</au><au>GONZÁLEZ LÓPEZ, LUIS JAVIER</au><au>RAMOS GÓMEZ, YASSEL</au><au>BETANCOURT NÚÑEZ, LÁZARO HIRAM</au><au>PERERA NEGRÍN, YASSER</au><au>GOMEZ, DANIEL EDUARDO</au><au>SÁNCHEZ PUENTE, ANIEL</au><au>GIL VALDÉS, JEOVANIS</au><au>RODRÍGUEZ ULLOA, ARIELIS</au><au>ALONSO, DANIEL FERNANDO</au><au>BESADA PÉREZ, VLADIMIR</au><au>ACEVEDO CASTRO, BORIS ERNESTO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS</title><date>2013-04-30</date><risdate>2013</risdate><abstract>This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; pol |
| recordid | cdi_epo_espacenet_PL1997506TT3 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | USE OF CK2 INHIBITOR FOR THE TREATMENT AND CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A36%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FERN%C3%81NDEZ%20DE%20COSSIO%20DORTA%20DUQUE,%20JORGE&rft.date=2013-04-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPL1997506TT3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |